Clinical Trials

Clinical Trials

Are There Clinical Trial Opportunities at the Community Level?

In this clinical trials highlight, Ken Getz explains how clinical research environments are changing and why trials are no longer tied to one facility. Watch to find out if cancer patients cancer patients can participate from home and more.

Ken Getz, MBA, Andrew Schorr

Clinical Trials

How Are Patient Insights Used to Ease Clinical Trial Requirements?

How are clinical trials being developed with a patient-centric approach? Watch now to learn about the design process and what role sponsors play to relieve some burdens and to focus more on cancer patients.

Ken Getz, MBA, Andy Lee, Andrew Schorr

Patient Power is Power. The more knowledge I have, it makes it easier to deal with my husband’s illness.

— Survey respondent

Latest News

Clinical Trials

Why It’s Important to Consider a Clinical Trial

Lauren Evoy Davis

Clinical Trials

Why We Need to Increase Diversity in Clinical Trials

Lauren Evoy Davis

Clinical Trials

How a Delaware Hospital Does Cancer Clinical Trials Right

Kandie Dempsey, DBA, MS, RN, OCN, Andrew Schorr

Clinical Trials

Clinical Trials: Where Do I Start?

Andrew Schorr

Clinical Trials

Are Clinical Trials Recommended As an Initial Therapy?

Andy Lee

Clinical Trials

How Can Clinical Trial Sponsors Help Patients With Cost?

Andy Lee, Andrew Schorr

Clinical Trials

Are Clinical Trials Becoming More Accessible?

Ken Getz, MBA, Andy Lee, T.J. Sharpe, Andrew Schorr

Clinical Trials

Are Expensive Tests Covered by Medicare in Clinical Trials?

Mark Fleury, PhD, Laura Levaas

Clinical Trials

Is It Difficult to Participate in a Clinical Trial?

Ken Getz, MBA, Andy Lee, T.J. Sharpe, Andrew Schorr

Clinical Trials

Can Medicare and Medicaid Patients Participate in a Clinical Trial?

Mark Fleury, PhD, Laura Levaas

Clinical Trials

How Do Medicare and Medicaid Impact Clinical Trial Participation?

Laura McHugh, RN, Mark Fleury, PhD, Jeanne M. Regnante, Laura Levaas

Clinical Trials

Is Clinical Trial Participation Parallel to the Pace of Drug Development?

Mel Mann, MBA, M.Ed, Richard L. Schilsky, MD, FACP, FASCO, FSCT, Andrew Schorr